No Detail Found!

Effects of unilateral intravitreal bevacizumab on the contralateral eye having diabetic macular edema

Author(s)
Aziz Jan Bashir Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
Abdul Hannan Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
Salman Sohail Chaudhary Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
Sarah Zafar Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
Abdullah Naeem Syed Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
Syed Hassan Massana Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan
Abstract
Objective: To investigate the effect of unilateral intravitreal Bevacizumab on contralateral eye in bilateral diabetic macular edema. Study Design: Quasi-experimental study. Place and Duration of Study: Retina Department of Al-Shifa Trust Eye Hospital, Rawalpindi, from Sep to Dec 2020. Methodology: Thirty-two patients were enrolled with consecutive sampling. All the patients had clinically diagnosed diabetic macular edema having >275µm macular thickness on OCT. They were injected with 1.25mg/0.05mL of Bevacizumab in one eye. Baseline macular thickness was compared with 4 weeks follow up macular thickness, using Optical Coherence Tomography. Results: The central macular thickness in the untreated eye at baseline was 396.97 ± 29.79 µm and 388.34 ± 30.06 µm at 4 weeks (p-value=0.001). The difference in central macular thickness in treated and untreated eyes were 28.44 ± 4.11 µm and 19.81 ± 5.31 µm respectively (p-value = 0.001). There were statistically significant differences between these measurements. Conclusion: Injecting Bevacizumab in one eye for diabetic macular edema has statistically significant effect on the contralateral non-injected eye macular thickness.
Publication Details
Page(s) 2075-2077
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 71, Issue: 6, Year: 2021

Request the full text from PASTIC

Keywords
Bevacizumab, Central retinal thickness, Diabetic macular edema., Intravitreal injection
0

Citations

0

Downloads

83

Views